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BY-NC-ND license (http://creativecomAbstract Background/Purpose: To present clinical and laboratory features, treatment op-
tions, and outcome in patients with brucellar testicular infection and to compare them with
analogous in brucellar patients without testicular involvement.
Methods: Thirty four brucellar patients with testicular infection treated in two general hospi-
tals in the Republic of Macedonia, during the period 1998e2009, were retrospectively
analyzed. Their clinical and laboratory characteristics were compared with analogous in 364
male brucellar patients without testicular infection, who were treated at the same hospitals
during the same time period.
Results: Brucellar testicular infection was evident in 34 (8.5%) out of 398 male patients with
brucellosis. The median age of the patients was 46.5 years. In all patients testicular involve-
ment was presented as an acute form with a median duration of 5 days (range, 2e14 days) prior
to diagnosis. Twenty-three of the patients had at least one other simultaneous focal infection.
After starting with the treatment testicular infection lasted a median 10 days, range 7
e21 days. Brucellar patients with testicular infection when compared with other brucellar pa-
tients more frequently manifested fever (97% vs. 61%), concomitant spondylitis (32% vs. 16%),
and urinary system involvement (12% vs. 2%). Also, the relapse rate in patients with testicular
involvement was significantly higher (24% vs. 9%).
Conclusion: In endemic regions brucellosis should be taken into consideration in any patient
with testicular infection. Brucellar testicular involvement is usually characterized with a se-
vere acute clinical presentation and a high percentage of relapses which entails the need of
timely recognition and proper treatment duration of at least 60 days.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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+ MODELIntroductionHuman brucellosis is a zoonosis that is characterized by a
wide clinical heterogeneity affecting different systems of
the human body. Genitourinary involvement is among the
commonest focal manifestations of human brucellosis,1e4
presented as epididymo-orchitis, prostatitis, cystitis,
interstitial nephritis, pyelonephritis, immunoglobulin A
nephropathy, exudative glomerulonephritis, and renal and
testicular abscess.5,6 Brucellar epididymo-orchitis (BEO), by
far the commonest genitourinary manifestation, was
described for the first time by Hardy in 19287 and Wain-
wright in 1929.8 This focal manifestation is a result of urine
Brucella removal or as a blood-borne septic metastasis.9e11
Clinical presentation of BEO is most frequently acute,6,11e14
rarely subacute10,15,16 or chronic.6,15 BEO may cause com-
plications like necrotizing orchitis,5,17,18 testicular ab-
scess,11,15,19 infarction,17,20 atrophy,21 and suppurative
necrosis.17,20 Also, cases with aspermia and infertility have
been described.11,14,15
Characteristics and prognosis of BEO have been
described in many studies and communications, but
comprising a small number of patients.13,22e24 This clinical
entity is also rarely presented in studies related to the
Balkan Peninsula,10,11 a region where brucellosis is consid-
ered to be an endemic disease. In this retrospective study
we attempted to present the main demographic, clinical,
and laboratory features, therapeutical experiences and
outcome in patients with brucellar testicular infection in
the Republic of Macedonia as an endemic region and to
compare them with analogous in brucellar patients without
testicular involvement.
Methods
The medical records and follow-up protocols of 34 brucellar
patients with testicular infection treated at the De-
partments for Infectious Diseases in Veles and Bitola, Re-
public of Macedonia, during the period 1998e2009, were
retrospectively analyzed. Their clinical and laboratory
features were compared with analogous in 364 male bru-
cellar patients, 18 years or older, without testicular infec-
tion that were treated at the same hospitals during the
same period. The study was approved by the Ethics Com-
mittee of the Medical Faculty in Skopje, Republic of
Macedonia.
The diagnosis of brucellosis was based on clinical find-
ings compatible with brucellosis, supported by detection of
specific antibodies at significant titers and/or demonstra-
tion of at least a fourfold rise in antibody titer in serum
samples obtained 3e4 weeks apart. Antibody titers were
determined by the standard tube agglutination, Brucella
Coombs, and/or Brucellacapt assays as previously
described.25,26
All of the patients underwent standard diagnostic pro-
tocol including detailed history, physical examination, and
laboratory analysisderythrocyte sedimentation rate, C-
reactive protein, hemoglobin, white blood cells, lympho-
cytes, platelets, urine analysis, alanine aminotransferase,
and serological tests for brucellosis. Patients were treated
with various antimicrobial combinations that contained twoPlease cite this article in press as: Bosilkovski M, et al., Testicular inf
Immunology and Infection (2016), http://dx.doi.org/10.1016/j.jmii.20or three of the following antimicrobials: oral doxycycline
100e200 mg/d; oral rifampin, 900 mg/d; oral trimetho-
prim/sulfamethoxazole (co-trimoxazole) 960 mg twice
daily; and intramuscular gentamicin, 5 mg/kg/d. Genta-
micin was administered 7e14 days, and the other drugs
were given 45 days or longer if spondylitis, brucellosis of
the central nervous system or therapeutic failure was
evident. After finishing the treatment all patients were
followed-up clinically and serologically every other month
during the first 3 months, and every 3e4 months
afterwards.
The investigated patients were divided into two groups:
with (n Z 34) and without (n Z 364) testicular infection.
The comparisons were performed in terms of the de-
mographic and epidemiological data, clinical manifesta-
tions, laboratory characteristics, and outcome. Orchitis and
epididymitis were diagnosed by the presence of acute
scrotal pain, swelling and tender scrotal, and/or epidid-
ymal enlargement which were associated with the first
episode of the actual disease and could not be attributed to
other causes. Duration of testicular infection was defined
as the number of days that elapsed from the start of
treatment until the disappearance of all inflammatory
signs. Relapse was accepted as the reappearance of
symptoms and signs after the antibrucellar treatment was
completed and therapeutical failure as persistence of
symptoms and signs of the disease for more than 45 days of
antibiotic therapy initiation.
The Chi-square test or Fisher’s exact test (when Chi-
square could not be applied) were used for comparison of
qualitative variables between the groups. For quantitative
variables ManneWhitney U test was performed. A p-value
of < 0.05 was considered significant.Results
Among 398 male patients with brucellosis that were treated
during the analyzed period at the Departments for Infec-
tious Diseases in Veles and Bitola, 34 (8.5%) had testicular
involvement. Besides orchitis and/or epididymitis, 23 of the
patients had other coexisting focal forms of brucellosis: 13
peripheral arthritis; 11 spondylitis; three sacroiliitis; three
radiculitis; three cystitis; two respiratory; two gastroin-
testinal; and one each of bursitis, tendinitis, and pyelone-
phritis (some of the patients had more than 1 simultaneous
focal form). Out of the patients with brucellar testicular
infection 21 manifested orchitis, 12 epididymo-orchitis, and
one patient had epididymitis. Their distribution is pre-
sented in Table 1.
Testicular infection was the only manifestation of the
disease in four patients, and in 30 other patients besides
testicular, other symptoms and signs attributable to
brucellosis e.g., fever, sweating, arthralgia, headache, loss
of appetite, backache, malaise, hepatomegaly, spleno-
megaly, and osteoarticular involvement were also present.
In three patients testicular manifestations appeared par-
allel with the general signs and symptoms; in one patient
they were preceding them, whereas in the remaining 26
patients testicular infection appeared after initiation of
brucellosis. In all cases the clinical presentation was acute
and the brucellar etiology of testicular symptoms and signsection in brucellosis: Report of 34 cases, Journal of Microbiology,
16.02.004
Table 1 Distribution of testicular infections in 34 patients
with brucellosis.
Infection Orchitis Epididymitis Epididymo-orchitis Total
Left 11 1 5 17
Right 7 0 5 12
Bilateral 3 0 2 5
Total 21 1 12 34
Brucellar testicular infection 3
+ MODELwas achieved in a median of 5 days (range, 2e14 days) since
the beggining. The affected testicle was two to six times
enlarged in comparison to the unaffected one.
As presented in Tables 2 and 3 significant differences
between the two groups were found concerning the pres-
ence of fever, concomitant spondylitis, and urinary tract
involvement, as well as higher values of white blood cells
and C-reactive protein in favor of patients with testicular
involvement.
Patients were treated with various therapeutic combi-
nations and different time duration (Table 4). Combination
with rifampin/doxycycline/co-trimoxazole was performed
in 24 (70%) patients and 197 (54%) patients with and without
testicular infection, respectively. The combination
rifampin/doxycycline/gentamicin was used in 8 (24%) pa-
tients and 133 (37%) patients of the designated groups
respectively, whereas with the combination rifampin/
doxycycline were treated 2 (6%) of the patients and 34 (9%)
of the patients, respectively (p Z 0.181).
After initiation of therapy testicular infection lasted for
median of 10 days (range, 7e21 days). As shown in Table 5,
a significantly higher number of patients from the group
with testicular infection was followed for at least 6 months,Table 2 Demographic and clinical features in patients with and
Parameter Patients with BEO (n
Age (y) 46.5 (18e77)
Direct contact with animals 25 (74)
Illness duration prior to diagnosis (d) 30 (3e360)
Fever 33 (97)
Sweating 28 (82)
Arthralgias 28 (82)
Malaise 24 (71)
Weight loss 11 (32)
Hepatomegaly 19 (56)
Splenomegaly 11 (32)
Focal involvement 22 (65)
Spondylitis 11 (32)
Sacroiliitis 3 (9)
Peripheral arthritis 13 (38)
Respiratory system 2 (6)
Nervous system 3 (9)
Urinary system 4 (12)
Hematopoietic system 1 (3)
Hepatic and gastrointestinal system 2 (6)
Data are presented as median (range) or n (%).
* Fisher exact test.
BEO Z brucellar epididymitis/orchitis.
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Immunology and Infection (2016), http://dx.doi.org/10.1016/j.jmii.20and the frequency of relapses was also higher than in the
other group. Remarkably, all eight relapses in the group
with testicular involvement were in patients that were
treated for 45 days. No differences in demographic and
clinical parameter between patients with testicular infec-
tion that relapsed and those without relapses were noted
(data not shown). All four cases with therapeutic failure in
the group with testicular involvement had a concomitant
spondylitis which was the cause for failure. However, we
had no cases with necrotizing orchitis, atrophy, infarction,
testicular abscess, suppurative necrosis, or cases requiring
surgery.
Discussion
In our study testicular infection was found in 8.5% of male
patients with brucellosis, which is in agreement with data
in the literature (1.4e25%).3,5,12,13,27e30 The reasons for the
wide range of presented frequency in the literature are to
be explored in the characteristics of the examined popu-
lation, the used criteria for defining the entity, the used
diagnostic procedures as well as whether the study is a
prospective or retrospective one. Testicular microtraumas
or nonspecific infections in the past, as well as genetic
predisposition might be a speculative explanation why
some of the patients with brucellosis are prone to testicular
infection. Still, until now we do not have a satisfactory
answer.
Brucellar testicular infection is usually unilat-
eral,10,13,15,20,22 which was the case in most of our patients.
However, unlike other studies where simultaneous
involvement of the testicle and epididymis predomi-
nated,15,21,23,27 or there was an equal presentation of
orchitis and epididymo-orchitis17 in two-thirds of our serieswithout testicular involvement.
Z 34) Patients without BEO (n Z 364) p
40 (18e82) 0.068
251 (69) 0.580
30 (5e360) 0.110
221 (61) <0.001
279 (77) 0.449
309 (85) 0.695
263 (72) 0.836
98 (27) 0.497
190 (52) 0.681
92 (25) 0.367
225 (62) 0.740
57 (16) 0.013
47 (13) 0.786*
106 (29) 0.267
20 (5) 1.000*
13 (4) 0.148*
6 (2) 0.006*
24 (7) 0.711*
17 (5) 0.672*
ection in brucellosis: Report of 34 cases, Journal of Microbiology,
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Table 3 Laboratory characteristics in patients with and without testicular involvement.
Parameter Patients with BEO (n Z 34) Patients without BEO (n Z 364) p
Erythrocyte sedimentation rate (mm/h) 29 (2e90) 28 (2e103) 0.938
Hemoglobin (g/L) 135.5 (105e169) 137 (73e177) 0.277
White blood cells ( 109/L) 7.4 (4.1e15.1) 6.4 (2.8e16.0) 0.007
Lymphocytes (%) 32 (8e54) 34 (11e74) 0.200
Platelets ( 1012/L) 246 (115e622) 222 (93e491) 0.061
Cereactive protein (mg/L) 42 (12e164) 18 (2e290) <0.001
Alanine aminotransferase (>45 U/L) 12 (35) 123 (34) 0.859
Data are presented as median (range) or n (%).
BEO Z brucellar epididymitis/orchitis.
Table 4 Therapeutic options in patients with and without testicular involvement.
Therapeutic combination Patients with BEO: treated/followed 6 mo/relapsed Patients without BEO:
treated/followed 6 mo/relapsed
RþDþTMP-SMZa 16/16/7 162/131/17
RþDþGa 3/2/0 99/75/3
RþDa 2/2/1 32/16/3
RþDþTMP-SMZb 8/8/0 35/33/2
RþDþGb 5/5/0 34/29/0
RþDb 0 2/2/1
Total 34/33/8 364/286/26
a Therapy duration of 45 days.
b Therapy duration of >45 days.
BE/OZ brucellar epididymitis/orchitis; DZ doxycycline; GZ gentamicin; RZ rifampin; TMP-SMZZ trimethoprim/sulfamethoxazole.
4 M. Bosilkovski et al.
+ MODELof patients orchitis has been a predominating inflammation,
which might be due to using only clinical criteria in estab-
lishing the diagnosis. BEO may occur as an isolated brucellar
manifestation5 or it might be within a systemic generalized
disease. In the latter case BEO precedes the diseases,13
starts at the same time,14,18 or follows after the general
manifestations of brucellosis, which was the case with the
largest number of our patients. Even in endemic regions
brucellosis recognition is especially difficult when testicular
infection is either the first or only manifestation of the
disease.
In this study 68% of the patients with testicular infection
at the same time had another concomitant focal involve-
ment, osteoarticular in the first order. Simultaneous
infection of genital and other organ system in brucellosis isTable 5 Outcome in patients with and without testicular involv
Parameter Patients with BEO (n Z 34)
Defervescence (d) 2 (0e45)
Followed-up  6 mo 33 (97)
Favorable outcomea 21 (64)
Relapsea 8 (24)
Therapeutic failurea 4 (12)
a Calculated in patients followed for 6 months.
b Favorable outcome vs. relapses.
c Favorable outcome vs. relapses þ therapeutic failures.
Data are presented as median (range) or n (%).
BEO Z brucellar epididymitis/orchitis.
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Immunology and Infection (2016), http://dx.doi.org/10.1016/j.jmii.20the previously known phenomenon,13,14,17,21,31 usually with
much lower percentages than the percentage reported by
us. Simultaneous osteoarticular and testicular infection in
brucellosis was already described32 as well as spondylitis
and orchitis33,34 but much less frequently compared to our
investigations. There is only one study comprising seven
patients with BEO where frequency of coexisting focal
diseases, including those with osteoarticular involvement,
is similar to ours.13 We have no adequate sustainable ar-
guments about the frequent presence of spondylitis in our
patients with testicular infection, except for the fact that
the majority of our patients were treated in hospitals and
underwent careful clinical examinations and follow-up. By
contrast, in another study BEO was more frequently found
in patients without osteoarticular manifestations.35ement.
Patients without BEO (n Z 364) p
1 (0e35) 0.115
286 (79) 0.010
241 (84) 0.004b
26 (9)
19 (7) 0.003c
ection in brucellosis: Report of 34 cases, Journal of Microbiology,
16.02.004
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+ MODELPatients with BEO in our series were older in comparison
with other studies.6,10,13,18,20,22e24,36 Also, our examina-
tions did not confirm the notion that patients with BEO
were younger than those without testicular infection,6,15
which might be a result of the larger number of patients
with concomitant spondylitis that we had. We have shown
that patients with BEO significantly more often manifested
fever compared to those without this focal form. These
cases presented acute testicular infection and besides local
manifestations a lot of additional signs and symptoms pre-
dominated, including fever. The presence of urinary
symptoms in BEO has been described with a wide range
from 0%18 to 69%.27 This was one of the characteristics that
distinguished our patients with and without brucellar
testicular infection, and with the frequency of 12% was
similar to those reported by others.12,14 Also, higher CRP
levels and higher leukocyte counts were found in our pa-
tients with testicular infection than in brucellar patients
without BEO, which has been demonstrated in other
studies, too.6,15 In the literature, patients with BEO are
more frequently reported to have blood culture positivity,15
abdominal pain, lack of appetite and headache.6
Treatment of BEO is almost identical with treatment of
nonlocalized brucellosis and lasts for 45 days.10,12,13,22,23
However, there are reports presenting treatment duration
of 8 weeks17,21 or 12 weeks.14,16 Applying these therapeutic
regimens therapeutic failure rate ranges from 0%10 to
26.5%,18 and the frequency of relapses is from 0%10,16 to
25%.14 According to Roushan et al17 by increasing the
duration of therapy from 45 days to 60 days the percentage
of cured patients significantly increased. In our study, the
treatment duration of patients with testicular infection but
without simultaneous spondylitis or brucellosis of the cen-
tral nervous system lasted for 45 days.
Defervescence in our patients was comparable with
defervescence in some other studies,14,18 as was the time
for resolution of testicular signs.16,22 The reasons for ther-
apeutic failures in our patients with testicular involvement
were completely due to the concomitant spondylitis and
the frequency of relapses we had in this category of pa-
tients, although high, is comparable to the percentages
reported by others.11,14,22 When compared to patients
without testicular involvement, a significantly increased
rate of relapses was noted in the group with testicular
infection, which was also reported by Navarro-Martı´nez
et al.14 It is to be emphasized that relapses appeared in our
patients treated for 45 days, and there were no relapses in
patients treated for a longer period. Therefore, we think
that treatment duration in brucellar testicular infection
should be routinely extended to at least 60 days.
Our study has several limitations including retrospective
design, a limited number of patients, absence of bacteri-
ological isolation, not using ultrasound as a routine method
for diagnosis and follow-up of BEO, as well as absence of
spermograms. In endemic countries, besides other causes
for testicular infection like mumps, tuberculosis, gonor-
rhea, Chlamydia trachomatis or enterobacterial infection,
hydrocellae, testicular torsion and tumor,5,22,37 brucellosis
should have priority in the differential diagnostic consid-
erations. Therefore, until results from larger prospective
studies are obtained, our study has shown that testicular
involvement in brucellosis is a serious condition with acutePlease cite this article in press as: Bosilkovski M, et al., Testicular inf
Immunology and Infection (2016), http://dx.doi.org/10.1016/j.jmii.20and severe presentation, simultaneous infection of other
organ systems, and a high percentage of relapses. Conse-
quently, its fast and timely recognition and proper and
sufficient, long treatment duration are recommended
priorities.Conflict of interest
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